Letter to the Editor
Belimumab in systemic lupus erythematosus: Experience in clinical practice settings in a regional hospital
Belimumab en lupus eritematoso sistémico: experiencia en práctica clínica en un hospital comarcal
Leyre Riancho-Zarrabeitia
, Ignacio Villa Blanco, Montserrat Santos-Gómez, Elena Aurrecoechea
Corresponding author
Servicio de Reumatología, Hospital Sierrallana, Torrelavega, Cantabria, Spain
Read
3333
Timeswas read the article
1495
Total PDF
1838
Total HTML
Share statistics
array:24 [ "pii" => "S2173574319300693" "issn" => "21735743" "doi" => "10.1016/j.reumae.2018.02.005" "estado" => "S300" "fechaPublicacion" => "2020-03-01" "aid" => "1199" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "copyrightAnyo" => "2018" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Reumatol Clin. 2020;16:188-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1 "HTML" => 1 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S1699258X1830041X" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2018.02.004" "estado" => "S300" "fechaPublicacion" => "2020-03-01" "aid" => "1199" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Reumatol Clin. 2020;16:188-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1667 "formatos" => array:3 [ "EPUB" => 38 "HTML" => 1325 "PDF" => 304 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta al Editor</span>" "titulo" => "Belimumab en lupus eritematoso sistémico: experiencia en práctica clínica en un hospital comarcal" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "188" "paginaFinal" => "189" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Belimumab in systemic lupus erythematosus: Experience in clinical practice settings in a regional hospital" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Leyre Riancho-Zarrabeitia, Ignacio Villa Blanco, Montserrat Santos-Gómez, Elena Aurrecoechea" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Leyre" "apellidos" => "Riancho-Zarrabeitia" ] 1 => array:2 [ "nombre" => "Ignacio" "apellidos" => "Villa Blanco" ] 2 => array:2 [ "nombre" => "Montserrat" "apellidos" => "Santos-Gómez" ] 3 => array:2 [ "nombre" => "Elena" "apellidos" => "Aurrecoechea" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173574319300693" "doi" => "10.1016/j.reumae.2018.02.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574319300693?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X1830041X?idApp=UINPBA00004M" "url" => "/1699258X/00000016000002P2/v1_202005111112/S1699258X1830041X/v1_202005111112/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173574319300644" "issn" => "21735743" "doi" => "10.1016/j.reumae.2018.01.012" "estado" => "S300" "fechaPublicacion" => "2020-03-01" "aid" => "1193" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Reumatol Clin. 2020;16:189-90" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Livedoid vasculopathy in a patient with bullous pemphigoid and primary Sjögren's syndrome" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "189" "paginaFinal" => "190" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Vasculopatía livedoide en una paciente con penfigoide ampolloso y síndrome de Sjögren primario" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 585 "Ancho" => 750 "Tamanyo" => 38420 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical image of the skin lesions.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "María Isabel García Briz, Amelia Prats Máñez, Ramón García Ruiz, Almudena Mateu Puchades" "autores" => array:4 [ 0 => array:2 [ "nombre" => "María Isabel" "apellidos" => "García Briz" ] 1 => array:2 [ "nombre" => "Amelia" "apellidos" => "Prats Máñez" ] 2 => array:2 [ "nombre" => "Ramón" "apellidos" => "García Ruiz" ] 3 => array:2 [ "nombre" => "Almudena" "apellidos" => "Mateu Puchades" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X18300330" "doi" => "10.1016/j.reuma.2018.01.013" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X18300330?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574319300644?idApp=UINPBA00004M" "url" => "/21735743/00000016000002P2/v2_202005120734/S2173574319300644/v2_202005120734/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S217357431930070X" "issn" => "21735743" "doi" => "10.1016/j.reumae.2018.02.006" "estado" => "S300" "fechaPublicacion" => "2020-03-01" "aid" => "1200" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Reumatol Clin. 2020;16:187-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Switch from intravenous to subcutaneous abatacept: Our experience" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "187" "paginaFinal" => "188" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Cambio de abatacept intravenoso a subcutáneo: experiencia de nuestro centro" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Juan Carlos Nieto-González, Juan G. Ovalles-Bonilla, Eduardo Estrada, Indalecio Monteagudo" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Juan Carlos" "apellidos" => "Nieto-González" ] 1 => array:2 [ "nombre" => "Juan G." "apellidos" => "Ovalles-Bonilla" ] 2 => array:2 [ "nombre" => "Eduardo" "apellidos" => "Estrada" ] 3 => array:2 [ "nombre" => "Indalecio" "apellidos" => "Monteagudo" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X18300421" "doi" => "10.1016/j.reuma.2018.02.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X18300421?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217357431930070X?idApp=UINPBA00004M" "url" => "/21735743/00000016000002P2/v2_202005120734/S217357431930070X/v2_202005120734/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Belimumab in systemic lupus erythematosus: Experience in clinical practice settings in a regional hospital" "tieneTextoCompleto" => true "saludo" => "Dear Editor," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "188" "paginaFinal" => "189" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Leyre Riancho-Zarrabeitia, Ignacio Villa Blanco, Montserrat Santos-Gómez, Elena Aurrecoechea" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Leyre" "apellidos" => "Riancho-Zarrabeitia" "email" => array:1 [ 0 => "leriancho@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "Ignacio" "apellidos" => "Villa Blanco" ] 2 => array:2 [ "nombre" => "Montserrat" "apellidos" => "Santos-Gómez" ] 3 => array:2 [ "nombre" => "Elena" "apellidos" => "Aurrecoechea" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Reumatología, Hospital Sierrallana, Torrelavega, Cantabria, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Belimumab en lupus eritematoso sistémico: experiencia en práctica clínica en un hospital comarcal" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Belimumab (BLM), a soluble human monoclonal antibody which inhibits the stimulator factor of lymphocyte B (BLyS), is the only biologic drug approved for the treatment of system lupus erythematosus (SLE). It is recommended in patients with active SLE (excluding patients with severe renal compromise or compromise of the central nervous system), with positive antibodies and high grade disease activity despite standard treatment.</p><p id="par0010" class="elsevierStylePara elsevierViewall">We now present the clinical experience of BLM use in a regional hospital servicing a population of 165,000 inhabitants.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Eleven patients with SLE who had received BLM at some time were included. One hundred per cent were female, with a mean age at lupus diagnosis of 31.6<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>9.7 years. Regarding clinical manifestations that presented during the course of the disease, joints were most commonly affected (100%), followed by cutaneous (81%), haematological (64%), renal (27%), pulmonary (9%) and cardiac (9%) manifestations. One hundred per cent of patients presented positivity for antinuclear antibodies, with 27% being positive for anti-DNA native antibodies, 45% for anti-SSA antibodies and 36% for anti-SSB antibodies. 45% of patients presented with positivity for antiphospholipid antibodies and over one third presented with hypocomplementemia.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Regarding treatments prior to the initiation of BLM, 100% of patients had received antimalarial drugs, over 80% methotrexate and 27% azathioprine. Twenty seven per cent had received anti-TNF drugs, 18% cyclophosphamide and 18% leflunomide. One of the patients had received treatment with tacrolimus and rituximab. The mean age of the patients at treatment initiation with BLM was 38.9<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>9.6 years. The main manifestations for which treatment was prescribed were joint symptoms followed by cutaneous symptoms. Over 60% of patients underwent an improvement of cutaneous and joint symptoms, with no resolution of lymphopenia being observed in our patients. In 4 of them (37%), treatment was suspended due to ineffectiveness after a median duration of 12.2<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>7.3 months. Particular mention is of one patient who developed a type IV lupus nephritis during treatment. Treatment was not definitively suspended due to side effects in any cases but was temporarily suspended in one patient (9%) due to a respiratory infection. With regard to concomitant treatments, in 3 of them (27%) treatment with BLM led to reduced doses of concomitant treatment (methotrexate, mycophenolate) and it was not possible to assess the possible corticoid sparing effect given the retrospective nature of the study.</p><p id="par0025" class="elsevierStylePara elsevierViewall">There have been several reports of patient cohorts in U.S.A., Canada and Germany<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1–3</span></a> treated with BLM with favourable results on the reduction of activity, improvements in lab tests and steroid sparing. However, few data on clinical practice is available in Mexico. The OBSERVE<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a> study which included 64 patients with SLE, showed an improvement of ≥20%, ≥50%, ≥80% in 72%, 52% and 27% of cases, respectively. The BIOGEAS<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a> study which included 10 patients with SLE refractory to antimalarial drugs and at least one other immunosuppressant, where manifestations of BLM were mucocutaneous, reported a response rate to the drug of 80%, higher than that reported by our study and by the OBSERVE study.</p><p id="par0030" class="elsevierStylePara elsevierViewall">To conclude, in clinical practice BLM has proven to be an alternative therapy to consider in patients with LES with cutaneous manifestations or joints refractory to standard immunosuppressants.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Riancho-Zarrabeitia L, Villa Blanco I, Santos-Gómez M, Aurrecoechea E. Belimumab en lupus eritematoso sistémico: experiencia en práctica clínica en un hospital comarcal. Reumatol Clin. 2020;16:188–189.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.E. Collins" 1 => "M. Dall’Era" 2 => "H. Kan" 3 => "C. Macahilig" 4 => "C. Molta" 5 => "V. Koscielny" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/lupus-2015-000118" "Revista" => array:6 [ "tituloSerie" => "Lupus Sci Med" "fecha" => "2016" "volumen" => "3" "paginaInicial" => "e000118" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26835146" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1569904814002523" "estado" => "S300" "issn" => "15699048" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Z. Touma" 1 => "A. Sayani" 2 => "C.A. Pineau" 3 => "I. Fortin" 4 => "M. Matsos" 5 => "G.A. Ecker" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-017-3682-9" "Revista" => array:6 [ "tituloSerie" => "Rheumatol Int" "fecha" => "2017" "volumen" => "37" "paginaInicial" => "865" "paginaFinal" => "873" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28280970" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "First real-world insights into belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in Germany: results from the OBSErve Germany Study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Schwarting" 1 => "J.O. Schroeder" 2 => "T. Alexander" 3 => "M. Schmalzing" 4 => "C. Fiehn" 5 => "C. Specker" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40744-016-0047-x" "Revista" => array:6 [ "tituloSerie" => "Rheumatol Ther" "fecha" => "2016" "volumen" => "3" "paginaInicial" => "271" "paginaFinal" => "290" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27804088" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluation of use of belimumab in clinical practice settings (observe study) in Spain: health resource utilization and labour absenteeism" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Cortes" 1 => "J.L. Andreu" 2 => "J. Calvo" 3 => "A.M. García-Aparicio" 4 => "C.G. Coronell" 5 => "S. Diaz-Cerezo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jval.2014.08.1703" "Revista" => array:5 [ "tituloSerie" => "Value Health" "fecha" => "2014" "volumen" => "17" "paginaInicial" => "A534" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27201706" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "AB0542 blocking the human B lymphocyte stimulator molecule (BLYS) using a monoclonal antibody (belimumab) in systemic lupus erythematosus: first results in real-life Spanish patients with refractory disease (Biogeas-Semi Registry)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Brito Zeron" 1 => "L. Caminal-Montero" 2 => "A. Chamorro" 3 => "A. de la Hera Fernández" 4 => "A. Gato" 5 => "Marín-Ballvé" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2014" "volumen" => "73" "paginaInicial" => "985" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735743/00000016000002P2/v2_202005120734/S2173574319300693/v2_202005120734/en/main.assets" "Apartado" => array:4 [ "identificador" => "8400" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735743/00000016000002P2/v2_202005120734/S2173574319300693/v2_202005120734/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574319300693?idApp=UINPBA00004M" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 9 | 9 | 18 |
| 2024 October | 44 | 25 | 69 |
| 2024 September | 46 | 23 | 69 |
| 2024 August | 58 | 47 | 105 |
| 2024 July | 61 | 29 | 90 |
| 2024 June | 46 | 26 | 72 |
| 2024 May | 49 | 25 | 74 |
| 2024 April | 48 | 36 | 84 |
| 2024 March | 49 | 20 | 69 |
| 2024 February | 35 | 17 | 52 |
| 2024 January | 35 | 18 | 53 |
| 2023 December | 22 | 29 | 51 |
| 2023 November | 40 | 48 | 88 |
| 2023 October | 35 | 49 | 84 |
| 2023 September | 53 | 43 | 96 |
| 2023 August | 50 | 26 | 76 |
| 2023 July | 37 | 24 | 61 |
| 2023 June | 33 | 22 | 55 |
| 2023 May | 28 | 26 | 54 |
| 2023 April | 19 | 17 | 36 |
| 2023 March | 37 | 23 | 60 |
| 2023 February | 31 | 26 | 57 |
| 2023 January | 15 | 16 | 31 |
| 2022 December | 44 | 34 | 78 |
| 2022 November | 28 | 29 | 57 |
| 2022 October | 57 | 38 | 95 |
| 2022 September | 44 | 29 | 73 |
| 2022 August | 39 | 37 | 76 |
| 2022 July | 33 | 40 | 73 |
| 2022 June | 43 | 25 | 68 |
| 2022 May | 31 | 37 | 68 |
| 2022 April | 26 | 29 | 55 |
| 2022 March | 34 | 48 | 82 |
| 2022 February | 27 | 17 | 44 |
| 2022 January | 46 | 35 | 81 |
| 2021 December | 28 | 37 | 65 |
| 2021 November | 24 | 36 | 60 |
| 2021 October | 25 | 47 | 72 |
| 2021 September | 41 | 37 | 78 |
| 2021 August | 26 | 26 | 52 |
| 2021 July | 20 | 36 | 56 |
| 2021 June | 37 | 24 | 61 |
| 2021 May | 31 | 38 | 69 |
| 2021 April | 66 | 69 | 135 |
| 2021 March | 52 | 20 | 72 |
| 2021 February | 32 | 16 | 48 |
| 2021 January | 24 | 21 | 45 |
| 2020 December | 33 | 18 | 51 |
| 2020 November | 19 | 16 | 35 |
| 2020 October | 20 | 13 | 33 |
| 2020 September | 23 | 18 | 41 |
| 2020 August | 4 | 1 | 5 |
| 2020 January | 1 | 0 | 1 |
Show all
